Results 161 to 170 of about 6,619 (182)

Application of a Mechanistic Model to Evaluate Putative Mechanisms of Tolvaptan Drug-Induced Liver Injury and Identify Patient Susceptibility Factors. [PDF]

open access: yesToxicological Sciences, 2017
Tolvaptan is a selective vasopressin V2 receptor antagonist, approved in several countries for the treatment of hyponatremia and autosomal dominant polycystic kidney disease (ADPKD).
Paul B Watkins   +2 more
exaly   +2 more sources

Tolvaptan: A Review in Autosomal Dominant Polycystic Kidney Disease

Drugs, 2015
Hannah A Blair, Gillian M Keating
exaly  

Mechanisms of Tolvaptan-Induced Toxicity in HepG2 Cells

Biochemical Pharmacology, 2015
Yuanfeng Wu   +2 more
exaly  

In Vitro P-Glycoprotein Interactions and Steady-State Pharmacokinetic Interactions Between Tolvaptan and Digoxin in Healthy Subjects

Journal of Clinical Pharmacology, 2011
Suresh Mallikaarjun   +2 more
exaly  

Tolvaptan

Reactions Weekly, 2012
openaire   +1 more source

Tolvaptan

Reactions Weekly, 2013
openaire   +2 more sources

Tolvaptan, an Oral Vasopressin Antagonist, in the Treatment of Hyponatremia in Cirrhosis

Journal of Hepatology, 2012
Andres Cardenas   +2 more
exaly  

Tolvaptan

Drugs of the Future, 2002
null Sorbera, L.A.   +3 more
openaire   +1 more source

Home - About - Disclaimer - Privacy